A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: PsA (Psoriatic Arthritis)

In brief

This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The target population is patients with active psoriatic arthritis. A total of 222 subjects are planned to be included.

Key facts

Study ID

NCT07315061

Run by

InventisBio Co., Ltd

People needed

222

Starts

2026-01-16

Expected to finish

2028-08-06

Last updated by the study team

2026-04-22

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects voluntarily take part in the study after being fully informed, sign a written informed consent form (ICF), and agree to follow procedures specified in the study protocol;
• Males and females, 18 to 70 years of age, inclusive at the time of signing of ICF;
• Have had an psoriatic arthritis of ≥ 3 months in duration prior to signing of ICF;
• Have had active arthritis, characterized by at least ≥3 tender joints (68 joint tenderness counts) and ≥3 swollen joints (66 joint swelling counts).

You may not qualify if…

• History of infection as defined in the protocol;
• Any of the medical diseases or disorders listed in the protocol;
• Significant, uncontrolled or unstable disease in any organ.

Where it is running

• West China School of Medicine — Chengdu, Sichuan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.